|
Depressive disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Our data suggest that markers in the RGS1 gene might be in linkage disequilibrium with a protective allele that reduces the risk of anxiety and depressive disorders.
|
23324853 |
2013 |
|
Depressive disorder
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that markers in the RGS1 gene might be in linkage disequilibrium with a protective allele that reduces the risk of anxiety and depressive disorders.
|
23324853 |
2013 |
|
Dermatitis, Allergic Contact
|
0.300 |
Biomarker
|
disease |
CTD_human |
Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization.
|
17374397 |
2007 |
|
Dermatologic disorders
|
0.300 |
Biomarker
|
group |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Poisoning, Inorganic
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Nervous System, Organic Arsenic Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Poisoning
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Encephalopathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Arsenic Induced Polyneuropathy
|
0.300 |
Biomarker
|
disease |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Osteosarcoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles.
|
14767549 |
2004 |
|
Multiple Sclerosis
|
0.130 |
GeneticVariation
|
disease |
GWASCAT |
Novel multiple sclerosis susceptibility loci implicated in epigenetic regulation.
|
27386562 |
2016 |
|
Multiple Sclerosis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
Presence of the HLA-DRB1*15 and the MS risk genotypes for SNPs in the RGS1, IRF5 and OLIG3/TNFAIP3 gene regions correlated significantly with increased levels of CXCL13.
|
23175382 |
2013 |
|
Multiple Sclerosis
|
0.130 |
GeneticVariation
|
disease |
BEFREE |
We also report that activation of the TNF-α pathway results in altered expression of 6 other MS susceptibility genes, including T-cell activation rho GTPase activating protein (TAGAP) and regulator of G-protein signaling 1 (RGS1), which are not previously known to be responsive to TNF-α.
|
24174586 |
2013 |
|
Multiple Sclerosis
|
0.130 |
Biomarker
|
disease |
BEFREE |
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci.
|
20555355 |
2010 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Regulator of G‑protein signaling 1 (RGS1) has been found to be a critical factor in melanoma and other malignancies.
|
29620236 |
2018 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, we found that RGS1 may promote melanoma progression through the downstream effects of Gαs signaling, such as the increased phosphorylation of AKT and ERK by western blotting.
|
29620236 |
2018 |
|
melanoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In the molecularly defined low-risk subgroup, patients treated with high-dose IFN had a significantly improved RFS compared with patients in the other two subgroups (<i>P</i> < 0.05).<b>Conclusions:</b> These results validate the independent impact of combined expression levels of SPP1, RGS1, and NCOA3 on survival of melanoma in a prospectively collected cohort.<i></i>.
|
28790109 |
2017 |
|
Celiac Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The co-dominant model of genotype effect confirmed the significant associations between RGS1 rs2816316/IL12A rs17810546 and CD.
|
27043536 |
2016 |
|
Celiac Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The RGS1 risk allele is shared with celiac disease (CD), and the IL12A risk allele seems to be protective for celiac disease.
|
20555355 |
2010 |
|
Celiac Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
Common variation in IL2/IL21, RGS1, IL12A/SCHIP and SH2B3 was associated with susceptibility to CD in our Italian cohort.
|
18805825 |
2009 |
|
melanoma
|
0.030 |
Biomarker
|
disease |
LHGDN |
Multivariate Cox regression analysis showed that increasing RGS1 immunostaining had an independent impact on the relapse-free survival (P=0.0069) and DSS (P=0.0077) of this melanoma cohort.
|
18580492 |
2008 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
In addition, 2 genes, CTGF and RGS1 were found to be upregulated in late stage cancer compared to early stage cancer, suggesting that they might be involved in cancer progression.
|
16353136 |
2006 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
The 1R20 gene has been localised by fluorescence in situ hybridisation to chromosome band 1q31, a region known to be implicated in the pathogenesis of haemopoietic malignancies.
|
8241276 |
1993 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Long non-coding RNA TUG1 recruits miR‑29c‑3p from its target gene RGS1 to promote proliferation and metastasis of melanoma cells.
|
30720136 |
2019 |
|
Autoimmune Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
In multivariate analyses, the overall effect of non-HLA SNPs on both phenotypes was evident, associations with RGS1 and CCR3-CCR5 region were confirmed and additional associations were implicated: NRP1, FUT2, and CD69 for children with multiple autoimmune diseases.
|
29182645 |
2017 |